Captor Therapeutics Spolka Akcyjna
CTX.WA · WSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | PLN 0 | PLN 2,010 | PLN 2,606 | PLN 2,954 |
| % Growth | -100% | -22.9% | -11.8% | – |
| Cost of Goods Sold | -PLN 2,021 | PLN 2,593 | PLN 873 | PLN 2,147 |
| Gross Profit | PLN 2,021 | -PLN 583 | PLN 1,733 | PLN 807 |
| % Margin | – | -29% | 66.5% | 27.3% |
| R&D Expenses | PLN 11,565 | PLN 10,189 | PLN 10,537 | PLN 7,524 |
| G&A Expenses | PLN 1,316 | PLN 4,354 | PLN 2,888 | PLN 3,101 |
| SG&A Expenses | PLN 1,316 | PLN 4,354 | PLN 2,888 | PLN 1,600 |
| Sales & Mktg Exp. | PLN 0 | PLN 0 | PLN 0 | -PLN 1,501 |
| Other Operating Expenses | PLN 953 | -PLN 4,381 | -PLN 976 | PLN 2,664 |
| Operating Expenses | PLN 13,834 | PLN 10,162 | PLN 12,449 | PLN 11,788 |
| Operating Income | -PLN 11,813 | -PLN 10,745 | -PLN 10,716 | -PLN 10,981 |
| % Margin | – | -534.6% | -411.2% | -371.7% |
| Other Income/Exp. Net | PLN 336 | PLN 990 | -PLN 3 | PLN 26 |
| Pre-Tax Income | -PLN 11,477 | -PLN 9,755 | -PLN 10,719 | -PLN 8,760 |
| Tax Expense | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| Net Income | -PLN 11,477 | -PLN 9,755 | -PLN 10,719 | -PLN 8,760 |
| % Margin | – | -485.3% | -411.3% | -296.5% |
| EPS | -2.08 | -1.77 | -1.95 | -1.59 |
| % Growth | -17.5% | 9.2% | -22.6% | – |
| EPS Diluted | -2.08 | -1.77 | -1.95 | -1.59 |
| Weighted Avg Shares Out | 5,529 | 5,517 | 5,496 | 5,496 |
| Weighted Avg Shares Out Dil | 5,529 | 5,519 | 5,496 | 5,496 |
| Supplemental Information | – | – | – | – |
| Interest Income | PLN 391 | PLN 853 | PLN 275 | PLN 167 |
| Interest Expense | PLN 61 | PLN 36 | PLN 104 | PLN 125 |
| Depreciation & Amortization | PLN 1,000 | PLN 1,313 | PLN 1,226 | PLN 1,123 |
| EBITDA | -PLN 10,416 | -PLN 9,432 | -PLN 9,390 | -PLN 7,512 |
| % Margin | – | -469.3% | -360.3% | -254.3% |